TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGAGlobeNewsWire • 10/16/23
TransCode Therapeutics stock skyrockets on positive brain cancer trial resultsProactive Investors • 09/25/23
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138GlobeNewsWire • 09/25/23
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical TrialGlobeNewsWire • 08/23/23
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business UpdateGlobeNewsWire • 08/14/23
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138GlobeNewsWire • 07/31/23
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAiNewsfile Corp • 07/13/23
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 07/10/23
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast CancerGlobeNewsWire • 06/22/23
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in GlioblastomaGlobeNewsWire • 06/06/23
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical TrialGlobeNewsWire • 04/27/23
TransCode Therapeutics Announces Strategic Expansion of its Product PortfolioGlobeNewsWire • 04/26/23
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of GlioblastomasGlobeNewsWire • 04/14/23
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138GlobeNewsWire • 04/05/23
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred StockGlobeNewsWire • 04/05/23